FULLERTON, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Agencourt Bioscience Corporation, a Beckman Coulter company, announced today that its Genomic Services played an important role in a newly released study from Johns Hopkins Kimmel Cancer Center. The study follows a major report last year that announced the discovery of 200 genes linked to breast and colon cancers. This second report completes the study of the vast majority of protein-coding genes and catalogs the genetic changes that occur during tumorigenesis. Three Agencourt individuals -- James Hartigan, Douglas R. Smith and Erick Suh -- were among the authors of the study, "The Genomic Landscape of Human Breast and Colorectal Cancers," published in Science Express last week.
All of the sequencing work and data generation for the study were done by Agencourt's Genomic Services, which has a long-standing relationship with the Johns Hopkins Kimmel Cancer Center scientists.
According to a news release issued by the Johns Hopkins Kimmel Cancer Center, scientists involved in the study found that most cancer-causing gene mutations are quite diverse and can vary from person to person. Of the 70 to 80 genes that are mutated in an individual cancer, about 15 are likely to contribute to the cancer's key characteristics, and most of these genes are different for each patient. With no more higher-frequency mutations (such as p53) on the horizon, researchers can focus on these less-commonly mutated genes and the complicated protein pathways that link them. Personalized cancer genomic research paves the way for tailored therapies and diagnostics focusing on the alterations identified in a particular patient's cancer.
"The research findings have important implications in the development of personal genomics, including molecular diagnostic tests, which are of great interest to Beckman Coulter," commented Erick Suh, Genomic Services director for Agencourt. "As the leading provider of DNA sequencing services, we have developed strong relationships with leading cancer research teams such as Johns Hopkins and are proud to contribute to these scientific advancements."
Agencourt Bioscience Corporation, a wholly owned subsidiary of Beckman Coulter, is a leading provider of nucleic acid purification products and genomic services for life science research. The company's products and services are based on the patented Agencourt SPRI(R) (Solid Phase Reversible Immobilization) paramagnetic bead-based technology.
Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion. For more information, visit http://www.beckmancoulter.com.
To view the Johns Hopkins Kimmel Cancer Center news release please copy and paste the following link into your browser: http://www.hopkinskimmelcancercenter.org/news/index.cfm?documentid=931&newstyp e=News%20Releases&action=showthisitem
CONTACT: Lynn Doucette-Stamm, Ph.D. of Agencourt Bioscience Corporation,
+1-978-867-2670, firstname.lastname@example.org; or Jennifer Dahlgren of Dahlgren
Communications, +1-530-265-0538, email@example.com, for Agencourt Bioscience
Web site: http://www.beckmancoulter.com/